Vir Biotechnology News

Latest Vir Biotechnology Stock News & VIR Headlines

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

3 days ago | businesswire.com

Vir Biotechnology Announces Proposed Public Offering

3 days ago | businesswire.com

Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48

6 days ago | marketbeat.com

Vir Biotechnology: Fairly Valued After Phase 3 Success?

6 days ago | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript

6 days ago | seekingalpha.com

Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment

6 days ago | investors.com

Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know

6 days ago | zacks.com

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta

7 days ago | gurufocus.com

Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data

7 days ago | businesswire.com

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta

7 days ago | businesswire.com

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

Market Closed

VIR

Vir Biotechnology

$ 9.96

-17.82%

Last 24H

Trading with leverage comes with a high risk and may not be suitable for everyone.

Portfolio

Updated 2 days ago

Top

Gainers

Losers

Symbol

Last Price

24H CNG

Vir Biotechnology News

Latest Vir Biotechnology Stock News & VIR Headlines

Download App

People Also Watch

Explore our Tools